Upload
kartthik-shanmugam
View
224
Download
0
Embed Size (px)
Citation preview
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
1/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
2/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
3/61
They won the Noble
Prize in 1989 for
proving that viruses
contain a cancer-causing gene derived
from the genome ofthe organism they
infect.
Specifically, they
showed that chicken
Rous Sarcoma Virus(RSV) carried an
oncogene called v-
src and this gene wasan intronless version of
a normal chickengene called c-src.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
4/61
Cellular functions related to growth andproliferation.
The proteins encoded by them function as Growth factor/ receptor
Signal transducers
Transcription factors
Cell cycle component
Mutation converts them into constitutivelyactive oncogene/oncoprotein.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
5/61
Ras geneMyc gene
Myc-IgH
FusionBcr-AblFusion
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
6/61
Oncogene causes cancer by affecting:
1. Cell Proliferation: (example;Ras, Raf, EGF)
2. Cell differentiation (example,PML/RAR that inhibitsthe differentiation of promyelocyte to granulocyte which
will maintain the cell in its active proliferate state)
3. Cell Survival (example;Pl-3/AKTwhich will activate
BCL-2 inhibit Apoptosis & Maintain cell survival.)
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
7/61
1. Growth Factor (example, Epithelium growth factor EGF ,
and platelet derived growth factor PDGF)
2. Growth Factor Receptor (Example; PDGFR)3. Signal transudation (example; Ras, Raf, & MEK)
4. Transcription Factor (example; Jun, Fos, Elk-1 & myc)
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
8/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
9/61
Growth factore.g. SIS oncogene (PDGF)- low-grade
astrocytomas and osteosarcomas
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
10/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
11/61
Growth factor receptor RET is a receptor forGCDNF mutation causesMEN 2A
and 2B FLT3 AML
PDGFR in CMML ERB B1- 80% ofsquamous cellcarcinomas of thelung,in
50% ormore of high-gradeastrocytomas calledglioblastomas,in80% to100% of head and neck tumors,and less commonly, in carcinomas of the urinary bladderand the gastrointestinal tract.
the ERB B2 gene ( HER 2/Neu) is amplified in approximately25% of breast cancers and in human adenocarcinomasarising within the ovary, lung, stomach, and salivaryglands.
a mutation in c-KIT, (also known as steel factor)in GIST
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
12/61
G proteins (signal transduction) - RAS
Point mutation of RAS familygenesis thesinglemost commonabnormality ofdominantoncogenes in human tumors
reduce the GTPase activity of the RAS proteins. The mutations generally involve codons 12, 59, or
61 of HRAS,KRAS,and NRAS.
Colonand pancreatic tumors - KRAS, bladdertumors have HRASmutations,and hematopoietic
tumors - NRASmutations. RAS is also involved in regulation of the cell cycle
RAS proteins can indirectly regulate the levels ofcyclins by activating the MAP kinase pathwayand the AP-1 transcription factor.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
13/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
14/61
RAF and MAP Kinase are also involved in
oncogenesis.
BRAF, a member of RAF - 60% ofmelanomas and in more than 80% of
benign nevi
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
15/61
CHROMOSOMALTRANSLOCATION/
REARRANG
EM
ENT
C-ABL TK
BCR-ABLIN CML
POINT MUTATION OFNEGATIVE REGULATORY
DOMAIN
JAK 2
STAT INPCV/ET/PMF
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
16/61
Nuclear transcription factors implicated asoncogenes e.g. MYC,MYB,JUN,FOS and
REL. MYC
transcription factor that can act in concert toreprogram somatic cell into pleuripotent cell.
C-MYC in burkitts, some cases of breast, colonand lung ca
N-MYC Neuroblastoma
L-MYC-Small cell ca of lung
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
17/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
18/61
Cyclins
Cyclin D in mantle cell lymphoma t(11;14).
Cyclin E in BRCA 1 mutated breast ca
CDK
AmplificationCDK4 gene melanoma,sarcoma and GBM
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
19/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
20/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
21/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
22/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
23/61
Tumor suppressor genes apply brakes
to cell proliferation.
These gene helps in regulating the cellgrowth and differentiation at various
stages of cell cycle.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
24/61
Two main cell cycle checkpoints - G1/S transition andG2/M transition.
To function properly, cell cycle checkpoints requiresensors of DNA damage, signal transducers, and effector
molecules. The sensors and transducers of DNA damage seem to be similar
for the G1/S and G2/M checkpoints. They include, as sensors,proteins of the RAD family and ataxia telangiectasia mutated(ATM) and as transducers, the CHK kinase families.
In the G1/S checkpoint, cell cycle arrest is mostly mediatedthrough p53, which induces the cell cycle inhibitor p21.
Arrest of the cell cycle by the G2/M checkpoint involves bothp53-dependent and p53-independent mechanisms.Defects incell cycle checkpoint components are a major cause of geneticinstability in cancer cells.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
25/61
CIP/KIP family: p21, p27 (CDKN2A-C) Block the cell cycle by binding to cyclin-CDK
complexes;
p21 is induced by the tumor suppressor p53; p27 responds to growth suppressors such as TGF-
.
INK4/ARF family (CDKN1A-D) p16/INK4a binds to cyclin DCDK4 and promotes
the inhibitory effects of RB; p14/ARF increases p53 levels by inhibiting
MDM2 activity
Mutations causes pancreatic ca, familialmelanoma and sq cc of esophagus.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
26/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
27/61
The genes normal function is to regulatecell division. Both alleles need to be
mutated or removed in order to lose thegene activity.
The first mutation may be inherited orsomatic.
The second mutation will often be a grossevent leading to loss of heterozygosity inthe surrounding area.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
28/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
29/61
RB, the first, and prototypic, tumorsuppressor gene discovered.
Approximately 60% of retinoblastomas aresporadic, and the remaining are familial,with the predisposition to develop thetumor being transmitted as an autosomaldominant trait.
Patients with familial retinoblastoma arealso at greatly increased risk of developingosteosarcoma and other soft-tissuesarcomas.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
30/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
31/61
A child carrying an inherited mutant RB allele in all somaticcells is perfectly normal (except for the increased risk ofdeveloping cancer).
Heterozygosity for the RB gene does not affect cell
behavior and cancerdevelops when thecell becomeshomozygous forthemutant allele,a condition knownasLOH, forloss of heterozygosity).
Similarly,one or more genes on the short arm ofchromosome 11 play a role in the formation of Wilms' tumor,hepatoblastoma, and rhabdomyosarcoma.
The von Hippel-Lindau (VHL) gene is a tumor suppressorgene that causes familial clear cell renal carcinomas and isalso involved in sporadic forms of the same tumor.
Consistent andnonrandom LOH has providedimportantclues to thelocation ofseveral tumorsuppressorgenes.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
32/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
33/61
Thep53 gene is located on chromosome 17p13.1 .
is the most common target for genetic alteration in
human tumors. critical gatekeeper against the formation of
cancer/Molecular policeman.
center of a large network of signals that sensecellular stress, such as DNA damage, shortenedtelomeres, and hypoxia
inheritance of one mutant allele - Li-Fraumeni syndrome, have a 25-fold greater chanceof developing a malignant tumor by age 50 than thegeneral population.
80% of point mutations present in human cancers -DNA-binding domain of the protein
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
34/61
p53 thwarts neoplastic transformation by
three interlocking mechanisms:
activation of temporary cell cycle arrest(quiescence),
induction of permanent cell cycle arrest
(senescence), triggering of programmed cell death
(apoptosis).
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
35/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
36/61
Chk1 and Chk2 kinases are serine/threonine kinases that are activated by the ATM and ATRkinases in response to DNA damage.
Ashwell S , Zabludoff S Clin Cancer Res 2008;14:4032-4037
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
37/61
p53 links cell damage with DNA repair, cellcycle arrest, and apoptosis.
Hence it is considered guardian of genome.
The new members of p53 family are p63 -differentiation of stratified squamous
epithelia p73 - strong pro-apoptotic effects after DNA
damage induced by chemotheraputic agents Mutations in Three musketeers is seen in the so-
called basal subset of breast cancers and poorprognosis.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
38/61
Adenomatous polyposis coli(APC)genes a class of tumor suppressors
whose main function is to down-regulate growth-promotingsignals.
Germ-line mutations at the APC(5q21) loci are associated withfamilial adenomatous polyposis.
a component of the WNTsignaling pathway,which has amajor role in controlling cellfate, adhesion, and cell polarityduring embryonic development
down-regulate -catenin.
Dysregulation of the APC/-catenin pathway causes Colonic carcinoma HCC Hepatoblastoma
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
39/61
TGF- potent inhibitor of proliferation. Dimerization of the receptor
upon ligand binding leads toactivation of the kinase andphosphorylation of receptorSMADs (R-SMADs).
R-SMADs can enter the nucleus,bind to SMAD-4, and activatetranscription of genes, includingthe CDKIs p21 and p15/INK4b.
leads to repression of c-MYC,CDK2, CDK4, and cyclins A andE.
TGF- type II receptor are seen in
cancers of the colon, stomach,and endometrium
SMAD 4 mutations causespancreatic and coloniccarcinoma.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
40/61
PTEN (Phosphatase and tensinhomologue)
a membrane-associatedphosphatase
chromosome 10q23 that is
mutated in Cow
densyndrome, an autosomaldominant disorder marked byfrequent benign growths, suchas tumors of the skinappendages, and anincreased incidence ofepithelial cancers, particularly
of the breast , endometrium,and thyroid. a tumor suppressor by serving
as a brake on the pro-survival/pro-growth PI3K/AKTpathway.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
41/61
NF1 gene
develop numerous benignneurofibromas and opticnerve gliomas as a result ofinactivation of the secondcopy of the gene and is calledneurofibromatosis type 1
Neurofibromin, the proteinproduct of the NF1 gene,contains a GTPase-activatingdomain,which regulatessignal transduction throughRAS proteins.
Neurofibromin facilitatesconversion of RAS from anactive to an inactive state.
With loss of neurofibrominfunction, RAS is trapped in anactive, signal-emitting state
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
42/61
NF2 gene predispose to the development of
neurofibromatosis type 2,benignbilateral schwannomas of the acousticnerve.
somatic mutations affecting both allelesof NF2 have also been found in sporadicmeningiomas and ependymomas.
The product of the NF2 gene, calledneurofibromin 2 or merlin, shows a great deal of homology with
the red cell membrane cytoskeletalprotein 4.1
is related to the ERM (ezrin, radixin, andmoesin) family of membranecytoskeleton-associated proteins.
is a key member of the Salvador-Warts-Hippo (SWH) tumor suppressor pathway,originally described in Drosophila.
controls organ size during developmentby modulating cell growth, proliferation,and apoptosis.
Many human homologues of genes inthe SWH pathway have been implicatedin human cancers
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
43/61
Von Hippel-Lindau (VHL) gene - chromosome 3p hereditary renal cell cancers,
pheochromocytomas,hemangioblastomas of the centralnervous system, retinal angiomas, andrenal cysts.
Mutations of the VHL gene have alsobeen noted in sporadic renal cellcancers .
The VHL protein is part of a ubiquitinligase complex. In the presence of oxygen, HIF1 is
hydroxylated and binds to the VHLprotein, leading to ubiquitination andproteasomal degradation.
in hypoxic environments the reaction
cannot occur, and HIF1 escapesrecognition by VHL and subsequentdegradation.
HIF1 can then translocate to thenucleus and turn on many genes, suchas the growth/angiogenic factorsvascular endothelial growth factor(VEGF) and PDGF.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
44/61
PTCH1 and PTCH2
are tumor suppressor genes thatencode a cell membrane protein(PATCHED), which functions as areceptor for a family of proteinscalled Hedgehog.
The Hedgehog/PATCHED pathwayregulates several genes, includingTGF- and PDGFRA and PDGFRB.
Mutations in PTCH are related toGorlin syndrome, an inheritedcondition also known as nevoidbasal cell carcinoma syndrome .
PTCH mutations are present in 20%
to 50% of sporadic cases of basalcell carcinoma.
About one half of such mutationsare of the type caused by UVexposure.
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
45/61
The WT1 gene located on chromosome 11p13, is associated with
the development of Wilms' tumor, a pediatric kidney
WT1 protein is a transcriptional activator of genesinvolved in renal and gonadal differentiation. Itregulates the mesenchymal-to-epithelial transitionthat occurs in kidney development.
a variety of adult cancers, including leukemias and
breast carcinomas, have also been show
n tooverexpress WT1.
Another Wilms' gene, WT2, located on 11p15, isassociated with the Beckwith-Wiedemannsyndrome
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
46/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
47/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
48/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
49/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
50/61
p53 in cases of NSCLC
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
51/61
FLOURESCENT IN SITUHYBRIDISATION for bcr-abl
transcript
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
52/61
A
C
BA; Normal bronchial
ept, Fhit +
B; Fhit mod +
C, Fhit
POLYMERASE CHAIN REACTION
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
53/61
TARGE
TED
THERAPY
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
54/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
55/61
55
Metastases
Carcinoma
Late adenoma
Intermediate adenoma
Early adenoma
Hyperproliferative epithelium
Normal epithelium5q mutation or
loss APC gene
12p mutation
KRAS
18q loss DCC
17p loss p53
Other alterations
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
56/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
57/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
58/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
59/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
60/61
8/3/2019 Tumor Suppressor Gene & Proto-Oncogene
61/61